Patients eligible for inclusion meet all of the following criteria:
Established IBD diagnosis (UC or CD).
Active disease: clinically active disease of the bowel is defined as at least mild activity using dedicated scoring indices or biochemically active disease as defined by a fecal calprotectin \> 60 µg/g
Patients must be eligible for adalimumab or risankizumab therapy.
Age of 18 years
Written informed consent
Clinical indication for an endoscopic procedure
For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs, or are less than 2 years postmenopausal:
A negative pregnancy test (urine or blood test) must be available.
You may not be if
A female study patient who is pregnant or provides breastfeeding
A female study patient of premenopausal age who does not use any reliable form of contraception at the time of adalimumab-680LT and/or risankizumab 800CW administration
Medical or psychiatric conditions that compromise the patient's ability to give informed consent
Prior anti-TNFα therapy in the last 6 weeks before inclusion
Previous treatment with adalimumab and detectable anti-adalimumab antibody levels
